Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer

References

• Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev 1985;12:251–70
   PubMed Web of Science ®Google Scholar
• Smith IE. Recurrent disease. In: Harris JR, Hellman S, Henderson IC, editors. Breast diseases. Philadelphia (PA) Lippincott; 1987. p. 369–84
   Google Scholar
• Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1986;319:516–8
   Google Scholar
• Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991;12(Suppl 1):1–6
   PubMed Web of Science ®Google Scholar
• Van Breukelen FJM, Bijvoet OLM, Van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet 1979;1: 803–5
   Google Scholar
• Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Br J Cancer 1988;58: 621–5
   Google Scholar
• Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast cancer. Br Med J 1988;297:772–3
   PubMed Web of Science ®Google Scholar
• Thiebaud D, Leyvraz S, von Fliedner V, et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991;27:37–41
   PubMed Web of Science ®Google Scholar
• van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:491–8
   Google Scholar
• Prise P, Hoskin PJ, Easton D, Yarnold JR. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986;6:247–55
   PubMed Web of Science ®Google Scholar
• Hoskin PJ. Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv 1988;7:69–86
   PubMedGoogle Scholar
• Schocker JD, Brady LW. Radiation therapy for bone metastasis. Clin Orthop 1982;169:38–43
   PubMed Web of Science ®Google Scholar
• Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial-Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846–54
   PubMed Web of Science ®Google Scholar
• Kouloulias VE, Dardoufas CE, Kouvaris JR, et al. Use of image processing techniques to assess effect of disodium pamidronate in conjunction with radiotherapy in patients with bone metastases. Acta Oncol 2002;41:169–74
   PubMed Web of Science ®Google Scholar
• Kouloulias V, Matsopoulos G, Kouvaris J, et al. Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys 2003;57:143–57
   PubMed Web of Science ®Google Scholar
• Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378–91
   PubMed Web of Science ®Google Scholar
• Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:3434–7
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Lipton A, et al. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038–44
   PubMed Web of Science ®Google Scholar
• Elomaa I, Blomqvist C, Grohn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983;1(8317):146–9
   PubMed Web of Science ®Google Scholar
• Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, BorgstromG. Treatemnt of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987;8(Suppl 1):53–6
   Google Scholar
• Kouloulias V, Kouvaris J, Antypas C, et al. An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Strahlenther Oncol 2003;179:471–9
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Tsilika E, Befon S, Kouloulias V, Vlahos L. Optimizing hospital-based home care for dying cancer patients: a population-based study. Palliat Med 1999;13:385–92
   Google Scholar
• Siegel S, Castellan Jr. J. Nonparametric statistics for the behavioral sciences, 2nd ed. McGraw Hill, College Div; 1988
   Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70
   PubMedGoogle Scholar
• Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187–220
   Google Scholar
• Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone lesions. New Engl J Med 1996;335:1785–91
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl J Med 1996;334:488–93
   PubMed Web of Science ®Google Scholar
• Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59–65
   PubMed Web of Science ®Google Scholar
• Elomaa I, Blomqvist C, Porkka L, et al. Diphosphonates for osteolytic metastases. Lancet 1985;1:1155–6
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 1989;116:1–28
   PubMedGoogle Scholar
• de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. New Engl J Med 1996;335:1016–21
   PubMed Web of Science ®Google Scholar
• Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320–2
   PubMed Web of Science ®Google Scholar
• Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55:273–86
   PubMed Web of Science ®Google Scholar
• Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991;49:407–15
   PubMed Web of Science ®Google Scholar
• Body J-J. Bisphosphonates. Eur J Cancer 1998;34:263–9
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10–7
   PubMed Web of Science ®Google Scholar
• Colleoni M, O’Neill A, Goldhirsch A, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 200;18: 3925–35
   Google Scholar
• Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289–93
   Google Scholar
• Vinholes J-J, Guo C-Y, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resoption markers in a randomised comparison of pamidronate or clodronate for hypercalcaemia of malignancy. J Clin Oncol 1996;15:131–8
   Google Scholar